Skip to main content

Table 2 Biodistribution of 18 F-FDG in mice bearing A431 tumors

From: Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression

Tissue

18F-FDG uptake level ((%ID/g)×kg)

Control

Gefitinib 100

Gefitinib 200

n = 8

n = 7

n = 7

Blood

0.046 ± 0.027

0.032 ± 0.019

0.037 ± 0.015

Tumor

0.129 ± 0.045

0.112 ± 0.023

0.111 ± 0.023

Muscle

0.022 ± 0.005

0.020 ± 0.007

0.020 ± 0.005

Heart

0.648 ± 0.587

0.709 ± 0.467

0.526 ± 0.587

Brown fat

0.372 ± 0.182

0.241 ± 0.090

0.290 ± 0.187

Lung

0.108 ± 0.017

0.100 ± 0.010

0.100 ± 0.010

Brain

0.171 ± 0.028

0.156 ± 0.020

0.172 ± 0.033

Spleen

0.115 ± 0.014

0.103 ± 0.013

0.113 ± 0.015

Liver

0.071 ± 0.033

0.055 ± 0.026

0.058 ± 0.018

Kidney

0.168 ± 0.029

0.122 ± 0.050

0.124 ± 0.036

Skin

0.162 ± 0.030

0.136 ± 0.042

0.149 ± 0.024

Tumor/muscle ratio

5.8 ± 1.4

5.9 ± 1.5

5.6 ± 1.1

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us